Large gap with delayed quotes
|
Last quote
07/03/2025
-
23:00:00
|
Bid
07/03/2025 -
18:59:59
|
Bid Volume |
Ask
07/03/2025 -
18:59:59
|
Ask Volume |
|---|---|---|---|---|
|
20.01
+0.13
(
+0.65% )
|
19.97
|
800 |
20.00
|
100 |
Analysis date: 01.07.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 01.07.2025.
Interest
Weak
Weak
Two stars since 01.07.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 17.06.2025 at a price of 16.67.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 13.06.2025.
4wk Rel Perf
3.86%
3.86%
The four-week dividend-adjusted overperformance versus SP500 is 3.86%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 04.02.2025.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.86%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.45%.
Mkt Cap in $bn
1.71
1.71
With a market capitalization <$2bn, BEAM THERAPEUTICS is considered a small-cap stock.
G/PE Ratio
-0.72
-0.72
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-3.68
-3.68
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-2.66%
-2.66%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
150
150
For 1% of index variation, the stock varies on average by 1.50%.
Correlation
0.40
0.40
Stock movements are strongly independent of index variations.
Value at Risk
10.84
10.84
The value at risk is estimated at USD 10.84. The risk is therefore 61.82%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
23.07.2021
23.07.2021